原始来源记录
决策级顶线结果
Quince Therapeutics：LAM-001用于PH-ILD的2b期数据预计于2028年第一季度公布
收购Orphai Therapeutics后，LAM-001被纳入Quince的管线。一项75例患者的PH-ILD 2b期试验正在进行中，顶线结果预计于2028年第一季度公布。另一项BOS 2期试验已完成入组，结果预计于2027年第一季度公布。
关键事实
来源摘录
EX-99.4 3 d163930dex994.htm EX-99.4 EX-99.4 Exhibit 99.4 BUSINESS Our Company We are a clinical-stage biopharmaceutical company developing a novel disease modifying therapeutic to address the significant unmet medical need associated with pulmonary disorders with few, if any, treatment options available. On May 18, 2026, we completed the acquisition of Orphai Therapeutics, a clinical-stage biopharmaceutical company developing therapies to treat serious, underserved pulmonary disorders. The acquisition brought into our pipeline Orphai’s lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of conditions associated with dysfunctional mammalian target of rapamycin (“mTOR”) activity that cann